PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Retatrutide: Research & Evidence

Ongoing Research

Published research, clinical trial data, and evidence grading for Retatrutide across studied indications.

Back to Retatrutide overview

Research Summary

Retatrutide is a novel triple agonist (GIP/GLP-1/glucagon) currently in Phase 3 clinical trials for obesity and type 2 diabetes. Phase 2 data showed the highest weight loss of any peptide to date (24% at 48 weeks) with significant metabolic improvements. FDA approval expected 2026-2027.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Weight loss (obesity) Tier B 2 Phase 2 trial showed up to 24% body weight reduction at 48 weeks — Phase 3 TRIUMPH program ongoing
Type 2 diabetes Tier B 2 Significant HbA1c reduction (-2.0%) in Phase 2; triple agonism provides enhanced metabolic benefits
NASH/MASH Tier C 1 Reduced liver fat content observed as secondary endpoint in Phase 2

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (6 sources)

  1. 1. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Clinical Trial

    Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, et al. (2025), The lancet. Diabetes & endocrinology

  2. 2. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Clinical Trial

    Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, et al. (2025), Diabetes, obesity & metabolism

  3. 3. Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. Review

    Misra S, Narayan RK, Kaur M (2025), Journal of basic and clinical physiology and pharmacology

  4. 4. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. Review

    Tewari J, Qidwai KA, Tewari A, Kaur S, Tewari V, et al. (2025), Expert review of clinical pharmacology

  5. 5. Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management. Meta-Analysis

    Ayesh H, Ayesh S, Niswender K (2024), American journal of therapeutics

  6. 6. Triple Agonism Based Therapies for Obesity. Review

    Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D (2025), Current cardiovascular risk reports